DPP4 Inhibitor on Glycemic Variability

• Status: Completed
• Trial end date: 2019-08-31
• Target enrollment: 0
• Participant gender: All

Summary

The investigators conducted a prospective study in patients with T2DM on twice daily MHI with or without metformin therapy. Blinded continuous glucose monitoring was performed at baseline and following 6 weeks of Vildagliptin therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Malaysia Sarawak
• Collaborator: Sarawak General Hospital
• Treatments: Vildagliptin

Criteria

Inclusion Criteria:

• HbA1c 7-10%

• Treated with stable dose of twice daily pre-mixed human insulin for at least 3 months, with or without metformin

Exclusion Criteria:

-